The Technical Analyst
Athersys Inc [ATHX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Athersys Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-33.50% $0.0135
America/New_York / 8 jan 2024 @ 15:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.833 mill |
| EPS: | -1.650 |
| P/E: | -0.0082 |
| Earnings Date: | Mar 29, 2024 |
| SharesOutstanding: | 61.72 mill |
| Avg Daily Volume: | 1.773 mill |
| RATING 2024-01-16 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0082 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0082 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0166 - 0.0286 ( +/- 26.55%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-18 | Hansen Maia | Sell | 67 | Common Stock |
| 2023-10-04 | Hansen Maia | Sell | 23 149 | Common Stock |
| 2023-10-04 | Camardo Daniel A. | Sell | 19 993 | Common Stock |
| 2023-09-18 | Hansen Maia | Sell | 67 | Common Stock |
| 2023-08-17 | Mayhugh Neema | Buy | 27 428 | NonQualified Stock Option (right to purchase) |
| INSIDER POWER |
|---|
| 22.73 |
| Last 94 transactions |
| Buy: 8 476 520 | Sell: 1 272 175 |
Forecast:
01:40 - $-0.0690
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0135 (-33.50% ) |
| Volume | 6.46 mill |
| Avg. Vol. | 1.773 mill |
| % of Avg. Vol | 364.60 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ATHX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ATHX
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Last 10 Buy Signals
Latest Press Releases
2023-11-16 08:30:00 - Press Release
Athersys Reports Third Quarter 2023 Financial Results And Business Highlights
Cleveland--(business wire)--athersys, inc. (otc: athx), a regenerative medicine company developing multistem® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended september 30, 2023 and provided a business update. third quarter 2023 and recent corporate and operational highlights: announced results of a blinded interim analysis of phase 3 masters-2 clinical trial studying multistem for treatment of ischemic stroke indicating.
2023-10-16 16:52:00 - Press Release
Athersys Extends Near Term Liquidity With Proceeds From Warrant Inducement And Global Ards License With Healios To Explore Strategic Alternatives
Cleveland--(business wire)--athersys, inc. (nasdaq: athx), (“athersys” or the “company”) a cell therapy and regenerative medicine company developing multistem® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to raise gross proceeds of up to approximately $3.9 million from the exercise of 28,124,590 warrants and received the first tranche payment of $1.5 million from healios k.k. (“healios”) under the acute respiratory distr.
2023-10-10 08:30:00 - Press Release
Athersys Reports Interim Analysis Results Of Masters-2 Clinical Study With Multistem In Ischemic Stroke, Signs Memorandum Of Understanding (mou) For Global Ards License With Healios
Cleveland--(business wire)--athersys, inc. (nasdaq: athx), a cell therapy and regenerative medicine company developing multistem® (invimestrocel) for critical care indications, announces that the independent data safety monitoring board (dsmb) has completed a pre-planned interim analysis of the company's ongoing phase 3 masters-2 pivotal clinical trial evaluating multistem® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients.
2023-10-03 16:30:00 - Press Release
Athersys Licenses Its Animal Health Assets To Ardent Animal Health
Cleveland & lexington, ky.--(business wire)--athersys, inc. (nasdaq: athx), a cell therapy and regenerative medicine company developing multistem® (invimestrocel) for critical care indications, and multipotent adult progenitor cell (mapc®) technology for equine, canine, and feline health applications, announces the signing of a licensing agreement with ardent animal health (ardent). ardent is a privately held veterinary biotechnology company developing regenerative medicine and cancer therapies.
2023-10-02 17:04:00 - Press Release
Athersys Director Jane Wasman Appointed Board Chair
Cleveland--(business wire)--athersys, inc. (nasdaq: athx), a regenerative medicine company developing multistem® (invimestrocel) for critical care indications, announces changes to its board of directors following the company's recent 2023 annual meeting of stockholders. current director jane wasman, jd, has been appointed board chair, effective september 28, 2023. ms. wasman has served as a director of the company since november 2020, currently serving as chair of athersys' audit committee and.
Latest News
2023-10-17 17:14:14 - InvestorPlace
Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
Longevity stocks have started to come on many investors' radars. These companies come with the promise of stable returns over the long run as human life continues to stretch further ahead.
2023-08-28 11:42:49 - PennyStocks
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding better ways to use the stock market to capture gains.
2023-08-25 11:06:16 - PennyStocks
7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?
Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing possibility of significant returns.
2023-08-18 09:04:02 - InvestorPlace
Why Is Athersys (ATHX) Stock Down 36% Today?
Athersys (NASDAQ: ATHX ) stock is falling on Friday after the biotechnology company announced a public stock offering. That public offering has Athersys selling 10,937,500 shares of ATHX stock for a price of 32 cents each.
2023-07-31 13:38:00 - Business Wire
Athersys to Host Business Update Conference Call on August 9th
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on August 9, 2023, at 4:30 p.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Willie Mays, Executive Vice President of Regenerative Medicine and Head of Neuroscienc.
2023-04-10 15:29:00 - Business Wire
Athersys to Host Business Update Conference Call on April 20th
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on April 20, 2023 at 11:00 a.m. Eastern Time.
2023-02-02 08:30:00 - Business Wire
Athersys to Host Business Update Conference Call on February 14th
CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (NASDAQ: ATHX), a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert “Willie” Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the Company's recent clinical and operational progress, upcoming milestones and vision for the year.
2022-11-15 16:19:10 - Seeking Alpha
Athersys, Inc. (ATHX) Q3 2022 Earnings Call Transcript
Athersys, Inc. (NASDAQ:ATHX ) Q3 2022 Earnings Conference Call November 15, 2022 11:00 AM ET Company Participants Ellen Gurley – Corporate Communications and Investor Relations Dan Camardo – Chief Executive Officer Kasey Rosado – Interim Chief Financial Officer Conference Call Participants Operator Good morning. My name is Devon and I will be your conference operator today.
2022-11-11 08:30:00 - Business Wire
Athersys to Present at Challenges and Opportunities for Mesenchymal Stem Cells Digital Conference and Participate in A.G.P.'s Biotech Conference
CLEVELAND--( BUSINESS WIRE )--Athersys, Inc. (Nasdaq: ATHX), a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced today its participation in two November conferences, the Challenges and Opportunities for Mesenchymal Stem Cells digital conference being held November 17-18, 2022 and A.G.P.'s Biotech Conference on November 30, 2022.
2022-10-25 08:30:00 - Business Wire
Athersys to Host Third Quarter Financial Results Call
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) will be hosting a conference call on Thursday, November 10, 2022, at 4:30 PM Eastern Time to review its third quarter 2022 financial results.